For example, ABT-737, an acrylsulfonamide-based pan Bcl-2 inhibitor that binds to Bcl-xL, Bcl-2 and Bcl-w, was shown to exert potent single-agent activity in leukemia and lymphoma cells lines as well as synergistic effect in combination with other anticancer drugs in leukemia and solid tumors (High et al. 2010; Konopleva et al. 2006; Oakes et al. 2012). Here, BCL2L1 is linked to leukemia.